Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) (2022 - 2026)
[304 Pages Report] The clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as increased R&D expenditure, growing demand for outsourcing of R&D activities, and the rising number of clinical trials for various diseases worldwide are driving the growth of the global market.
To know about the assumptions considered for the study, Request for Free Sample Report
Covid-19 Impact on the Global Clinical Trials Market
A number of established pharmaceutical and biopharmaceutical companies have scaled up R&D and manufacturing efforts to develop and distribute test kits, vaccines, and drugs against the SARS-CoV-2 virus. To expedite the R&D process, many pharmaceutical and biotechnology companies teamed up with clinical trial service providers through long-term agreements, partnerships, and collaborations across the globe. The pandemic phase posed several challenges for professionals operating in the market space and trial sponsors. This, in turn, has created a dynamic change in the market, particularly in terms of clinical trial supply and logistics.
The onset of SARS-CoV-2 infection compelled various biotechnology entities to rapidly develop and commercialize vaccines against COVID-19. As reported by the WHO, the vaccine candidate landscape for COVID-19 witnessed a significant boost in the second half of 2020. The WHO reported that more than 80 vaccines are presently in the clinical trial phase. This indicates that the demand for COVID-19 vaccine trials is expected to remain high in the next 2 to 3 years. Additionally, due to COVID-19, the demand for ready-to-plug-in infrastructure to expedite timelines of clinical trials amidst the restrictions imposed by the pandemic has increased.
This has specifically increased the demand for decentralized services. Clinical research entities have also developed dedicated services for COVID-19 research. In 2020, a number of new service launches and agreements, partnerships, and collaborations with different pharmaceutical companies and academic institutes for the research & development of COVID-19 vaccines, drugs, and diagnostics were recorded across the globe.
Clinical Trails Market Dynamics
Driver: Increasing investment in pharmaceutical R&D
Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in the development of novel drugs and devices. The pharmaceutical industry, in particular, is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that top pharma companies are increasing their R&D efficiencies through heavy investments in R&D (to see returns in the longer term) and collaborative R&D efforts. The rising R&D expenditure of pharmaceutical and biopharmaceutical companies is prompting them to opt for fully integrated or functional outsourcing services, from the early development stage to the late-stage development phase, for both drug discovery and development. As there is enormous pressure on these companies to contain fixed costs, outsourcing has evolved as a strategic alternative to overcome the lack of in-house resources required for new product development. Big pharmaceutical companies, in particular, are transitioning to a leaner business model that relies heavily on outsourcing. Most pharmaceutical and biopharmaceutical companies tend to outsource their testing functions during R&D to improve profitability, meet the timelines involved in drug development, and save costs. This is evident from the recent agreements by major pharmaceutical companies with CROs. The increasing number of drugs in the pipeline has made it necessary to outsource various drug development stages to manage capacities and access scientific and process innovations to develop cost-effective and efficient drug molecules. This trend is expected to drive the growth of the clinical trials market.
Challenges: Requirement of unique analytical testing approaches for innovative drug molecules
Over the years, competition in the pharmaceutical and biopharmaceutical market to develop cutting-edge therapies and gain patent exclusivity through quick drug development has increased significantly. In all phases of pharmaceutical and biopharmaceutical development, bioanalytical testing plays a major role and is the most outsourced process among all the chemistry, manufacturing, and control (CMC) activities. CMC data is also pivotal to meet regulatory expectations and acquire Investigational New Drug (IND) approval. The diversity of CMC requirements for biopharmaceutical IND and the development of novel drug delivery systems pose a variety of challenges and require a myriad of analytical methods for testing new drug molecules.
Opportunity: Need for novel clinical trial designs for complex cell and gene therapies
Cell and gene therapies are highly specific and hold the potential to address the unmet medical needs associated with treating several disorders. The promising therapeutic potential of these therapies has led many pharmaceutical companies and investors to put in a significant amount of capital towards developing and commercializing them. As of 2018, more than six gene therapy products have been approved in various countries. As of April 2021, 16 cell and gene therapies have been approved by the US FDA. In 2020, around 362 cell and gene therapies were under clinical development. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development, are increasing the demand for facilities that offer R&D services for these therapies.
As compared to traditional drugs, the R&D, manufacturing, and filing processes for cell and gene therapy products are more complex. Cell and gene therapy products also involve higher R&D expenses (including special requirements on manufacturing, transportation, storage, and clinical trials). Biotech companies and academic institutes increasingly rely on CROs for guidance throughout the development process, from protocol design, logistics, and site operations considerations to clinical trial data management. CROs have specialized skills, scientific expertise, and a consultative mindset to construct novel trial designs and operate successfully in these new models. Greater regulatory clarity and industry regulation on quality standards, increase in global multicenter clinical studies, and increasing government-industry collaborations driving basic biomedical research have increased the preference for CROs for cell and gene therapy development.
By phase, Phase III segment accounted for the largest share of the clinical trials market in 2020.
Based on phase, the market is segmented into Phase I, Phase II, Phase III, & Phase IV. The comparatively huge patient population and the use of sophisticated research services to study drug efficacy have contributed to the growth of Phase III segment. These complex clinical trials require both clinical resources and robust technologies to recruit patients efficiently, initiate trial sites quickly, and provide cost-effective and high quality study management. A majority of global pharmaceutical, biopharmaceutical, and medical device manufacturers outsource services for Phase III clinical trials to clinical trial service providers.
By service type, the laboratory services segment accounted for the largest share of the clinical trials market in 2020.
Based on service type, the clinical trial services market is segmented into protocol designing, site identification, patient recruitment, laboratory services, bioanalytical testing, analytical testing, clinical trial supply & logistic services, decentralized clinical services, clinical trial data management services, medical device testing services, and other services. The increasing number of clinical trial service providers offering a comprehensive range of laboratory services such as biospecimens and GMP services is projected to drive the growth of the segment.
By therapy area, infectious disease segment is projected to register the highest CAGR during the forecast period
Based on the therapy area, the clinical trials market is segmented into oncology, infectious diseases, cardiology, neurology, womens health, genetic diseases, immunology, and other therapy areas. The infectious diseases segment is projected to register the highest CAGR during the forecast period, owing to the increasing number of clinical trials for vaccines and drugs for COVID-19 and other infectious diseases and rising investments in R&D for infectious diseases.
By application, the small molecules segment accounted for the largest share of the clinical trials market in 2020.
Based on application, the global clinical trial market is segmented into small applications, vaccines, cell & gene therapy, and others. The others segment is inclusive of other large applications such as hormones/insulin and blood components. The large share of this segment can be attributed to the robust pipeline for generic drugs, which comprise a considerable chunk of the pharma business. The saturation of the pharma industry with simple generic products has also driven the investment in complex generic drug candidates; this is expected to drive the segment growth.
North America accounted for the largest share of the clinical trials market in 2020.
In 2020, North America accounted for the largest share of the market, followed by Europe. The large share of North America in this market can be attributed to the high-quality standards offered by service providers in the pharmaceutical industry, rapid growth in the biosimilar & biologics markets, and rising clinical trial activities in the region.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), PPD (US), and ICON Plc (US) are the prominent players operating in the clinical trials market.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
20192026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
20212026 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Phase, Service Type, Therapy Area, Application, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America and Middle East & Africa |
|
Companies Covered |
The major market players include including IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), Parexel International (US), PPD (US), ICON Plc (US), Medpace Holdings (US), SGS (Switzerland), PSI CRO AG (US), Axcent Advanced Analytics (US), BIO Agile Therapeutics (US), Firma Clinical Research (US), Acculab Life Sciences (US), Azelix (US), CTserv (US), Pepgra (UK), and Dove Quality Solutions (US), Novotech Health Holding (Australia), Geneticist Inc. (US), Linical Americas (US), Frontage Holding Corporation (US), and Celerion (US). |
The study categorizes the clinical trials market into the following segments and subsegments:
BY PHASE
- Phase I
- Phase II
- Phase III
- Phase IV
BY SERVICE TYPE
- Protocol Designing
- Site Identification
- Patient Recruitment
- Laboratory Services
- Bioanalytical Testing Services
- Cell-based Assays
- Virology Testing
- Method Development, Optimization, & Validation
- Serology, Immunogenicity, & Neutralizing Antibodies
- Biomarker Testing Services
- PK/PD (Pharmacokinetics/Pharmacodynamics) Testing Services
- Other Bioanalytical Testing Services
- Analytical Testing Services
- Clinical Trial Supply & Logistic Services
- Decentralized Clinical Services
- Clinical Trial Data Management Services
- Medical Device Testing Services
- Other Clinical Trial Services
BY THERAPY AREA
- Oncology
- Infectious Diseases
- Cardiology
- Neurology
- Women's Health
- Genetic Diseases
- Immunology
- Other Therapy Areas
BY APPLICATION
- Vaccine
- Cell & Gene Therapy
- Small Molecules
- Other Applications
BY REGION
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- The Middle East and Africa
Recent Developments
- In September 2021, Syneos Health entered into a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants.
- In April 2021, IQVIA acquired Q2 Solutions, a clinical laboratory services organization, from Quest Diagnostics.
- In November 2020, WuXi Apptec expanded its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP Plasmids
- In April 2020, IQVIA launched COVID-19 trial matching service to accelerate treatment and vaccine development against the COVID-19 pandemic in U.S. The company launched comprehensive online screener and trial matching tool for all COVID-19 trials in the US.
- In May 2020, IQVIA announced the Japan and Asia Pacific expansion of IQVIA Biotech to deliver integrated clinical solutions and support biotech and emerging biopharma companies.
Frequently Asked Questions (FAQ):
What is the current size of the global clinical trials market?
The clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period.
Who are the leading players in the clinical trials market?
Some of the leading players in the clinical trials market include IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), PPD (US), and ICON Plc (US).
What are the major therapy areas of the clinical trials market?
The clinical trials market therapy areas are segmented into oncology, infectious diseases, cardiology, neurology, womens health, genetic diseases, immunology, and other therapy areas. Oncology is the largest application segment in the clinical trials market in 2020.
What are the major drivers of the clinical trials market?
Some of the major drivers of the clinical trials market includes rising investment in pharmaceutical R&D to drive clinical trials market, increasing number of clinical trials and rising prevalence of orphan and rare diseases. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 CLINICAL TRIALS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 31)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 20212026
FIGURE 8 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 43)
FIGURE 12 CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026 (USD BILLION)
FIGURE 13 MARKET, BY THERAPY AREA, 2021 VS. 2026 (USD BILLION)
FIGURE 14 MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 15 MARKET, BY SERVICE TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET
4 PREMIUM INSIGHTS (Page No. - 47)
4.1 CLINICAL TRIALS MARKET OVERVIEW
FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH
4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2020)
FIGURE 18 PHASE III SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
4.3 MARKET, BY BIOANALYTICAL SERVICE TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 19 CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 50)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing investments in pharmaceutical R&D
FIGURE 21 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 20122026
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 20112021
5.2.1.2 Increasing number of clinical trials
FIGURE 23 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (20002021)
5.2.1.3 High cost of in-house drug development
FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 20102020 (USD BILLION)
5.2.1.4 Rising prevalence of orphan and rare diseases
5.2.2 OPPORTUNITIES
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic
FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (20012020)
TABLE 2 LIST OF BIOLOGICS APPROVED BY US FDA, 2020
5.2.2.2 Rising demand for specialized testing services among end users
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals for clinical trials
5.2.3.2 Requirement of unique analytical testing approaches for innovative drug molecules
5.2.4 MARKET TRENDS
5.2.4.1 Adoption of artificial intelligence-based tools for drug discovery
5.2.4.2 Increasing outsourcing activities in emerging Asian economies
5.2.4.3 Integrated end-to-end R&D service solutions
5.3 RANGES/SCENARIOS
FIGURE 26 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CLINICAL TRIALS MARKET
5.4 IMPACT OF COVID-19 ON THE CLINICAL TRIALS MARKET
5.5 PORTERS FIVE FORCES ANALYSIS
TABLE 3 CLINICAL TRIALS MARKET: PORTERS FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 DEGREE OF COMPETITION
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
FIGURE 27 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
5.7 ECOSYSTEM ANALYSIS
FIGURE 28 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET
TABLE 4 SUPPLY CHAIN ECOSYSTEM
5.8 REGULATORY ANALYSIS
6 CLINICAL TRIALS MARKET, BY PHASE (Page No. - 69)
6.1 INTRODUCTION
TABLE 5 CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
FIGURE 29 DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020
6.2 CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION
FIGURE 30 CLINICAL TRIAL PLANNING & DESIGNING
6.3 PHASE I
6.3.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT
TABLE 6 EXAMPLES OF PHASE I STUDY OF DRUGS
TABLE 7 PHASE I MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 8 NORTH AMERICA: PHASE I MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 9 EUROPE: PHASE I MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 10 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 20192026 (USD BILLION)
6.4 PHASE II
6.4.1 THE LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS
TABLE 11 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
TABLE 12 PHASE II MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 13 NORTH AMERICA: PHASE II MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 14 EUROPE: PHASE II MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 15 ASIA PACIFIC: PHASE II MARKET, BY COUNTRY, 20192026 (USD BILLION)
6.5 PHASE III
6.5.1 RISING COSTS OF PHASE III TRIALS INCREASE THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES
TABLE 16 EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY
TABLE 17 PHASE III MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 18 NORTH AMERICA: PHASE III MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 19 EUROPE: PHASE III MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 20 ASIA PACIFIC: PHASE III MARKET, BY COUNTRY, 20192026 (USD BILLION)
6.6 PHASE IV
6.6.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
TABLE 22 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 23 NORTH AMERICA: PHASE IV MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 24 EUROPE: PHASE IV MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 25 ASIA PACIFIC: PHASE IV MARKET, BY COUNTRY, 20192026 (USD BILLION)
7 CLINICAL TRIALS MARKET, BY SERVICE TYPE (Page No. - 84)
7.1 INTRODUCTION
TABLE 26 MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
7.2 PROTOCOL DESIGNING
7.2.1 PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES
TABLE 27 PROTOCOL DESIGNING MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 28 NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 29 EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 30 ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.3 SITE IDENTIFICATION
7.3.1 NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY
TABLE 31 SITE IDENTIFICATION MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 32 NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 33 EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 34 ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.4 PATIENT RECRUITMENT
7.4.1 THE GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT
TABLE 35 SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS
TABLE 36 PATIENT RECRUITMENT MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 37 NORTH AMERICA: PATIENT RECRUITMENT MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 38 EUROPE: PATIENT RECRUITMENT MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 39 ASIA PACIFIC: PATIENT RECRUITMENT MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.5 LABORATORY SERVICES
7.5.1 INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT
TABLE 40 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 41 LABORATORY SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 42 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 43 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 44 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.5.2 ANALYTICAL TESTING SERVICES
7.5.2.1 Increasing demand for analytical testing for drug development to drive the growth of this segment
TABLE 45 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 46 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 47 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 48 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6 BIOANALYTICAL TESTING SERVICES
7.6.1 HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 49 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 20192026 (USD BILLION)
TABLE 50 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 51 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 52 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 53 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6.2 CELL-BASED ASSAYS
7.6.2.1 Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment
TABLE 54 CELL-BASED ASSAYS MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 55 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 56 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 57 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6.3 VIROLOGY TESTING
7.6.3.1 Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment
TABLE 58 VIROLOGY TESTING MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 59 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 60 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 61 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6.4 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES
7.6.4.1 Rising importance of studies to determine the pharmacokinetic behavior of drug candidates to drive the growth of this segment
TABLE 62 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 63 NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 64 EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 65 ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6.5 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION
7.6.5.1 Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment
TABLE 66 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 67 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 68 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 69 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6.6 SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES
7.6.6.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth
TABLE 70 USEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 71 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 72 EUROPE: SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 73 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6.7 BIOMARKER TESTING SERVICES
7.6.7.1 Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth
TABLE 74 BIOMARKER TESTING SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 75 NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 76 EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 77 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.6.8 OTHER BIOANALYTICAL TESTING SERVICES
TABLE 78 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 79 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 80 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 81 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES
7.7.1 DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD
TABLE 82 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 83 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 84 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 85 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 86 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.8 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES
7.8.1 ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 87 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 89 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 90 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.9 DECENTRALIZED CLINICAL TRIAL SERVICES
7.9.1 THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS
TABLE 91 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 92 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 93 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 94 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.10 MEDICAL DEVICE TESTING SERVICES
7.10.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET
TABLE 95 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 96 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 97 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 98 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
7.11 OTHER CLINICAL TRIAL SERVICES
7.11.1 OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES
TABLE 99 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 20192026 (USD BILLION)
TABLE 100 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 101 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 102 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 20192026 (USD BILLION)
8 CLINICAL TRIALS MARKET, BY THERAPY AREA (Page No. - 122)
8.1 INTRODUCTION
TABLE 103 CLINICAL TRIALS MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
8.2 ONCOLOGY
8.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
FIGURE 31 GLOBAL CANCER INCIDENCE, BY TYPE (2020)
FIGURE 32 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND)
TABLE 104 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 105 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION, 20192026 (USD BILLION)
TABLE 106 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 107 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 108 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 20192026 (USD BILLION)
8.3 INFECTIOUS DISEASES
8.3.1 INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
TABLE 109 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 20192026 (USD BILLION)
TABLE 110 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 111 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 112 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20192026 (USD BILLION)
8.4 NEUROLOGY
8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 113 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
TABLE 114 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION, 20192026 (USD BILLION)
TABLE 115 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 116 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 117 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY, 20192026 (USD BILLION)
8.5 IMMUNOLOGY
8.5.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES
TABLE 118 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION, 20192026 (USD BILLION)
TABLE 119 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 120 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 121 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 20192026 (USD BILLION)
8.6 CARDIOLOGY
8.6.1 HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
TABLE 122 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 123 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION, 20192026 (USD BILLION)
TABLE 124 NORTH AMERICA: MARKET FOR CARDIOLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 125 EUROPE: MARKET FOR CARDIOLOGY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 126 ASIA PACIFIC: MARKET FOR CARDIOLOGY, BY COUNTRY, 20192026 (USD BILLION)
8.7 GENETIC DISEASES
8.7.1 PROMISING DRUGS IN THE PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH
TABLE 127 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION, 20192026 (USD BILLION)
TABLE 128 NORTH AMERICA: MARKET FOR GENETIC DISEASES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 129 EUROPE: MARKET FOR GENETIC DISEASES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 130 ASIA PACIFIC: MARKET FOR GENETIC DISEASES, BY COUNTRY, 20192026 (USD BILLION)
8.8 WOMENS HEALTH
8.8.1 THE RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN DRIVES MARKET GROWTH
TABLE 131 CLINICAL TRIALS MARKET FOR WOMENS HEALTH, BY REGION, 20192026 (USD BILLION)
TABLE 132 NORTH AMERICA: MARKET FOR WOMENS HEALTH, BY COUNTRY, 20192026 (USD BILLION)
TABLE 133 EUROPE: MARKET FOR WOMENS HEALTH, BY COUNTRY, 20192026 (USD BILLION)
TABLE 134 ASIA PACIFIC: MARKET FOR WOMENS HEALTH, BY COUNTRY, 20192026 (USD BILLION)
8.9 OTHER THERAPY AREAS
FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION)
TABLE 135 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)
TABLE 136 CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY REGION, 20192026 (USD BILLION)
TABLE 137 NORTH AMERICA: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 20192026 (USD BILLION)
TABLE 138 EUROPE: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 20192026 (USD BILLION)
TABLE 139 ASIA PACIFIC: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 20192026 (USD BILLION)
9 CLINICAL TRIALS MARKET, BY APPLICATION (Page No. - 143)
9.1 INTRODUCTION
TABLE 140 CLINICAL TRIAL MARKET, BY APPLICATION, 20192026 (USD BILLION)
9.2 SMALL MOLECULE
9.2.1 INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS THE GROWTH OF THIS SEGMENT
FIGURE 34 SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019
TABLE 141 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION, 20192026 (USD BILLION)
TABLE 142 NORTH AMERICA: MARKET FOR SMALL MOLECULES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 143 EUROPE: MARKET FOR SMALL MOLECULES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES, BY COUNTRY, 20192026 (USD BILLION)
9.3 VACCINES
9.3.1 OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON THE INDUSTRY OPERATIONS
FIGURE 35 COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT, BY PHASE (AS OF JANUARY 2022)
TABLE 145 MARKET FOR VACCINES, BY REGION, 20192026 (USD BILLION)
TABLE 146 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 147 EUROPE: MARKET FOR VACCINES, BY COUNTRY, 20192026 (USD BILLION)
TABLE 148 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY, 20192026 (USD BILLION)
9.4 CELL & GENE THERAPY
9.4.1 THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND OFFERINGS DRIVES THE SEGMENT GROWTH
FIGURE 36 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY INDICATION (AS OF 2020)
FIGURE 37 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020)
TABLE 149 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION, 20192026 (USD BILLION)
TABLE 150 NORTH AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 151 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 20192026 (USD BILLION)
TABLE 152 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 20192026 (USD BILLION)
9.5 OTHER APPLICATIONS
9.5.1 INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH
TABLE 153 MARKET FOR OTHER APPLICATIONS, BY REGION, 20192026 (USD BILLION)
TABLE 154 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20192026 (USD BILLION)
TABLE 155 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20192026 (USD BILLION)
TABLE 156 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20192026 (USD BILLION)
10 CLINICAL TRIALS MARKET, BY REGION (Page No. - 155)
10.1 INTRODUCTION
TABLE 157 CLINICAL TRIALS MARKET, BY REGION, 20192026 (USD BILLION)
10.2 NORTH AMERICA
FIGURE 38 NORTH AMERICA SNAPSHOT
TABLE 158 NORTH AMERICA: MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 159 NORTH AMERICA: MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 160 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 161 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 162 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 163 NORTH AMERICA: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.2.1 US
10.2.1.1 Robust clinical research activities to become a key factor supporting the US market growth
FIGURE 39 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES BY REGION (2020 VS. 2019)
TABLE 164 US: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 165 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 166 US: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 167 US: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 168 US: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.2.2 CANADA
10.2.2.1 Increasing number of clinical trials in Canada to support market growth
TABLE 169 CANADA: MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 170 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 171 CANADA: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 172 CANADA: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 173 CANADA: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.3 EUROPE
FIGURE 40 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
TABLE 174 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 175 EUROPE: MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 176 EUROPE: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 177 EUROPE: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 178 EUROPE: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 179 EUROPE: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.3.1 GERMANY
10.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials
TABLE 180 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 181 GERMANY: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 182 GERMANY: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 183 GERMANY: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 184 GERMANY: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.3.2 UK
10.3.2.1 Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth
FIGURE 41 UK: PHARMACEUTICAL R&D EXPENDITURE, 20132017 (USD MILLION)
TABLE 185 UK: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 186 UK: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 187 UK: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 188 UK: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 189 UK: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.3.3 FRANCE
10.3.3.1 High number of oncology clinical trials in France is expected to drive market growth in France
TABLE 190 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 191 FRANCE: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 192 FRANCE: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 193 FRANCE: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 194 FRANCE: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.3.4 ITALY
10.3.4.1 Low drug approval times along with the growing number of clinical trials in Italy to drive market growth
TABLE 195 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 196 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 197 ITALY: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 198 ITALY: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 199 ITALY: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 200 ITALY: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.3.5 SPAIN
10.3.5.1 Rising R&D expenditure to boost market growth for clinical trials in Spain
FIGURE 42 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 20112017
TABLE 201 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 202 SPAIN: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 203 SPAIN: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 204 SPAIN: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 205 SPAIN: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.3.6 REST OF EUROPE (ROE)
TABLE 206 ROE: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 207 ROE: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 208 ROE: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 209 ROE: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 210 ROE: MARKET, BY MOLECULE, 20192026 (USD BILLION)
10.4 ASIA PACIFIC (APAC)
FIGURE 43 ASIA PACIFIC SNAPSHOT
TABLE 211 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY, 20192026 (USD BILLION)
TABLE 212 ASIA PACIFIC: MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 213 ASIA PACIFIC: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 214 ASIA PACIFIC: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 215 ASIA PACIFIC: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 216 ASIA PACIFIC: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.4.1 CHINA
10.4.1.1 China dominates the clinical trials services market owing to a robust pharmaceutical industry and the presence of prominent clinical trial service providers
TABLE 217 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 218 CHINA: MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 219 CHINA: MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 220 CHINA: MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 221 CHINA: MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.4.2 JAPAN
10.4.2.1 Strong focus on R&D activities in Japan is expected to drive market growth
TABLE 222 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 223 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 224 JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 225 JAPAN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 226 JAPAN: CLINICAL TRIALS MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 227 JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.4.3 INDIA
10.4.3.1 Growing pharmaceutical industry in India to drive the market growth for clinical trails
TABLE 228 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 229 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 230 INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 231 INDIA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 232 INDIA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 233 INDIA: CLINICAL TRIALS MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 234 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 235 ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 236 ROAPAC: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 237 ROAPAC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 238 ROAPAC: CLINICAL TRIALS MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 239 ROAPAC: CLINICAL TRIALS MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.5 LATIN AMERICA
10.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET GROWTH IN LATIN AMERICA
TABLE 240 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 241 LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 242 LATIN AMERICA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 243 LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 244 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 20192026 (USD BILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA
TABLE 245 MEA: CLINICAL TRIALS MARKET, BY PHASE, 20192026 (USD BILLION)
TABLE 246 MEA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 20192026 (USD BILLION)
TABLE 247 MEA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 20192026 (USD BILLION)
TABLE 248 MEA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 20192026 (USD BILLION)
TABLE 249 MEA: CLINICAL TRIALS MARKET, BY APPLICATION, 20192026 (USD BILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 211)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 44 CLINICAL TRIALS MARKET: STRATEGIES ADOPTED
11.3 MARKET SHARE ANALYSIS
FIGURE 45 CLINICAL TRIALS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
11.4 COMPANY EVALUATION QUADRANT
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 46 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2020
11.5 COMPETITIVE BENCHMARKING
11.5.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
FIGURE 47 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET
11.5.2 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
FIGURE 48 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET
11.6 COMPETITIVE SCENARIO AND TRENDS
11.6.1 SERVICES LAUNCHES
TABLE 250 CLINICAL TRIALS MARKET: SERVICE LAUNCHES (JANUARY 2017-NOVEMBER 2020)
11.6.2 DEALS
TABLE 251 CLINICAL TRIALS MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021)
11.6.3 OTHER DEVELOPMENTS
TABLE 252 CLINICAL TRIALS MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020)
12 COMPANY PROFILES (Page No. - 222)
12.1 KEY COMPANIES
(Business Overview, Services, Recent Developments, MnM View)*
12.1.1 IQVIA
TABLE 253 IQVIA: BUSINESS OVERVIEW
FIGURE 49 IQVIA: COMPANY SNAPSHOT
TABLE 254 IQVIA: SERVICE OFFERINGS
TABLE 255 IQVIA: SERVICE LAUNCHES
TABLE 256 IQVIA: DEALS
TABLE 257 IQVIA: OTHER DEVELOPMENTS
12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE)
TABLE 258 LABCORP: BUSINESS OVERVIEW
FIGURE 50 LABCORP: COMPANY SNAPSHOT
TABLE 259 LABCORP: SERVICE OFFERINGS
TABLE 260 LABCORP: SERVICE LAUNCHES
TABLE 261 LABCORP: DEALS
TABLE 262 LABCORP: EXPANSIONS
12.1.3 SYNEOS HEALTH INC.
TABLE 263 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
FIGURE 51 SYNEOS HEALTH INC.: COMPANY SNAPSHOT
TABLE 264 SYNEOS HEALTH INC.: SERVICE OFFERINGS
TABLE 265 SYNEOS HEALTH INC: SERVICE LAUNCHES
TABLE 266 SYNEOS HEALTH INC.: DEALS
12.1.4 WUXI APPTEC
TABLE 267 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT
TABLE 268 WUXI APPTEC: SERVICE OFFERINGS
TABLE 269 WUXI APPTEC: SERVICE LAUNCHES
TABLE 270 WUXI APPTEC: DEALS
TABLE 271 WUXI APPTEC: EXPANSIONS
12.1.5 CHARLES RIVER LABORATORIES
TABLE 272 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 273 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS
TABLE 274 CHARLES RIVER LABORATORIES: DEALS
TABLE 275 CHARLES RIVER LABORATORIES: EXPANSIONS
12.1.6 PAREXEL INTERNATIONAL
TABLE 276 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW
TABLE 277 PAREXEL INTERNATIONAL: SERVICE OFFERINGS
TABLE 278 PAREXEL INTERNATIONAL: SERVICE LAUNCHES
TABLE 279 PAREXEL INTERNATIONAL: DEALS
TABLE 280 PAREXEL INTERNATIONAL: EXPANSIONS
12.1.7 PRA HEALTH SCIENCES
TABLE 281 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
FIGURE 54 PRA HEALTH SCIENCES: COMPANY SNAPSHOT
TABLE 282 PRA HEALTH SCIENCES: SERVICE OFFERINGS
TABLE 283 PRA HEALTH SCIENCES: SERVICE LAUNCHES
TABLE 284 PRA HEALTH SCIENCES: DEALS
TABLE 285 PRA HEALTH SCIENCES: EXPANSIONS
12.1.8 PPD INC
TABLE 286 PPD INC: BUSINESS OVERVIEW
FIGURE 55 PPD INC: COMPANY SNAPSHOT
TABLE 287 PPD INC: SERVICE OFFERINGS
TABLE 288 PPD: SERVICE LAUNCHES
TABLE 289 PPD: DEALS
TABLE 290 PPD: EXPANSIONS
12.1.9 ICON PLC
TABLE 291 ICON PLC: BUSINESS OVERVIEW
FIGURE 56 ICON PLC: COMPANY SNAPSHOT
TABLE 292 ICON PLC: SERVICE OFFERINGS
TABLE 293 ICON PLC: SERVICE LAUNCHES
TABLE 294 ICON PLC: DEALS
12.1.10 MEDPACE HOLDINGS INC
TABLE 295 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW
FIGURE 57 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT
TABLE 296 MEDPACE HOLDINGS INC: SERVICE OFFERINGS
TABLE 297 MEDPACE HOLDINGS INC: DEALS
TABLE 298 MEDPACE HOLDINGS INC: EXPANSION
12.1.11 ACM GLOBAL LABORATORIES
TABLE 299 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
TABLE 300 ACM GLOBAL LABORATORIES: SERVICE OFFERINGS
12.1.12 ADVANCED CLINICAL
TABLE 301 ADVANCED CLINICAL: BUSINESS OVERVIEW
TABLE 302 ADVANCED CLINICAL: SERVICE OFFERINGS
12.1.13 SGS
TABLE 303 SGS: BUSINESS OVERVIEW
FIGURE 58 SGS: COMPANY SNAPSHOT
TABLE 304 SGS: SERVICE OFFERINGS
TABLE 305 SGS: DEALS
12.1.14 FRONTAGE HOLDINGS CORPORATION
TABLE 306 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 59 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 307 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS
TABLE 308 FRONTAGE HOLDINGS CORPORATION: DEALS
TABLE 309 FRONTAGE HOLDINGS CORPORATION: EXPANSION
12.1.15 PSI CRO AG
TABLE 310 PSI CRO AG: BUSINESS OVERVIEW
TABLE 311 PSI CRO AG: SERVICE OFFERINGS
TABLE 312 PSI CRO AG: EXPANSIONS
12.1.16 BIO AGILE THERAPEUTICS
TABLE 313 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW
TABLE 314 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS
12.2 OTHER PLAYERS
12.2.1 AZELIX
TABLE 315 AZELIX: COMPANY OVERVIEW
12.2.2 CTSERV
TABLE 316 CTSERV: COMPANY OVERVIEW
12.2.3 PEPGRA
TABLE 317 PEPGRA: COMPANY OVERVIEW
12.2.4 AXCENT ADVANCED ANALYTICS (A3)
TABLE 318 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW
12.2.5 DOVE QUALITY SOLUTIONS
TABLE 319 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW
12.2.6 FIRMA CLINICAL RESEARCH
TABLE 320 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW
12.2.7 CELERION
TABLE 321 CELERION: COMPANY OVERVIEW
12.2.8 NOVOTECH HEALTH HOLDINGS
TABLE 322 NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW
12.2.9 GENETICIST INC.
TABLE 323 GENETICIST INC.: COMPANY OVERVIEW
12.2.10 LINICAL AMERICAS
TABLE 324 LINICAL AMERICAS: COMPANY OVERVIEW
*Details on Business Overview, Services, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 297)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORT
13.5 AUTHOR DETAILS
This technical, market-oriented, and financial study of the global clinical trials market involved extensive secondary sources, directories, and databases to identify and collect relevant information. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the clinical trials market (estimated through various research approaches) was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Data
The secondary sources referred to for this research study include publications from government sources, such as the Association of Clinical Research Organization (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICROS), Clinical and Contract Research Association (CCRA), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research. Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global clinical trials market, which was validated through primary research.
Primary Data
Extensive primary research was conducted after acquiring basic knowledge about the global clinical trials market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply-side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from tier 1 and tier 2 companies engaged in offering services) across five major regionsNorth America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 40% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Primary research was used in this report to:
- Validate the market segmentation defined through a product and service portfolio assessment of the leading players in the clinical trials market
- Understand key industry trends and issues defining the strategic growth objectives of market players
- Gather both demand- and supply-side validation of the key factors affecting the market growth (such as market drivers, challenges, and opportunities)
- Validate assumptions for the market sizing and forecasting model used for this study
- Understand the market position of leading players in the clinical trials market and their market shares/rankings
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total clinical trials market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Report Objectives
- To define, describe, and forecast the global clinical trials market based on phase, service type, therapy area, application, and region.
- To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
- To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total clinical trials market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the revenue of market segments with respect to five major regions:
North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa - To profile key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments in the clinical trials market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the rest of Europe clinical trials market, by country
- Further breakdown of the rest of Asia Pacific clinical trials market, by country
- Further breakdown of the Latin American and Middle Eastern & African clinical trials market, by country
Company Information
Detailed analysis and profiling of additional market players (up to 5) inclusive of:
- Business Overview
- Financial Information
- Product Offered
- Developments (Last three years)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Clinical Trials Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Clinical Trials Market
Which of the global leaders holds the largest share of the global Clinical Trials Market?
Can you share the detailed report on the geographical analysis of the global Clinical Trials Market?
Which segment, Based on the therapy area, accounted for the major share of the global Clinical Trials Market?